The influenza vaccine production, for a number of major customers serving global markets including Europe and Japan, exceeded 21 million prefilled syringes for the 2007 campaign. The new Catalent facility is a state-of-the-art prefilled syringe filling/finishing operation, purpose built for this activity, which doubles the available previous prefilled syringe capacity. Catalent received initial European regulatory approval for this facility in July 2006, and expects to have the first FDA...

Quadriplegic Woman to Receive Life-Changing Stem-Cell Therapy in Costa Rica, Family Asking for Public's Help Publish Date : 11/17/2007 6:26:00 AM Source : Mobile & Gadgets News OnlyPunjab.com Most homes in America have at least one or two old cell phones lying in a drawer or closet somewhere, not really doing anything except collecting dust. Quadriplegic Woman to Receive Life-Changing Stem-Cell Therapy in Costa Rica, Family Asking for Public's Help Publish Date : 11/17/2007 6:26:00 AM...

Enstice said the 15-acre industrial site, which is adjacent to the downtown Buffalo biotechnology campus, offers new possibilities for the burgeoning research and development facility. The original Chan Kreiger master plan is considered a world class design that melds state-ofthe- art biotech and medical research facilities with historic residential and commercial neighborhoods around it. This additional space presents a significant opportunity to grow a knowledge-based economy in Buffalo...

That seven-member economic development fund advisory board will help decide how to spend $3 million earmarked for boosting the county's young biotech prospects. Officials are looking for three members who have business ties to or live in the town, while the other two can live or run businesses outside of Jupiter's boundaries but still within the county's life science corridor. Palm Beach County will suggest one appointee to represent it, and so will the Paragon Foundation, the nonprofit...

Postbulletin.com: An 'elegant solution' for a common heart malady - Sat, Nov 17, 2007 Postbulletin.com Rochestermn.com RochesterMagazine.com Home Delivery . Contact Us . Advertising . Alerts . Archives . Site map . RSS . Login Rochester, MN's local news source. Postbulletin.com: An 'elegant solution' for a common heart malady - Sat, Nov 17, 2007 Postbulletin.com Rochestermn.com RochesterMagazine.com Home Delivery . Contact Us . Advertising . Alerts . Archives . Site map . RSS . Login...

Investor Relations . Privacy Policy . Terms of Use . Conflicts Policy . Corrections . Internet Index . Advertise . FAQ . Logout Site Map . Who's Who . Reader Feedback . Employment . Customer Service . Contact Us Subscribe to our RSS Feed Subscribe to our PODCAST. Looking ahead, Nastech's current $84 million enterprise value is much more reasonable, but my doubts about the company's nasal drug delivery technology have not been assuaged at all. The other big piece of the Nastech...

Under the terms of the deal, Celgene will acquire all the outstanding shares of Pharmion common stock for $72 per share, payable in a combination of cash and Celgene common stock. The deal is expected to close in the second quarter and be slightly dilutive to earnings in 2008 and accretive in 2009 and beyond.

It's an acronym for the company's asset-tracking business, Secure Asset Reporting Services; shareholders were told management "believes that the name change communicates the company's intent to adequately brand the company and describe its image. There's always a risk in such moves will the new name resonate with customers or investors? Does it distinguish the firm from its rivals? A rash of name-changing swept through local companies in recent weeks. Back in June the Clise family, Seattle...

Eurand has had four products approved by the FDA since 2001 and has a pipeline of product candidates in development for itself and its collaboration partners. More information about the NBI is available at www.nasdaq.com About Eurand Eurand is a specialty pharmaceutical company that develops enhanced pharmaceutical and biopharmaceutical products based on its proprietary drug formulation technologies. Eurand's technology platforms include bioavailability enhancement of poorly soluble drugs,...